Leishmaniasis is a neglected tropical disease (NTDs), endemic in 88 countries, affecting more than 12 million people. The treatment consists in pentavalent antimony compounds, amphotericin B, pentamidine and miltefosine, among others. However, these current drugs are limited due to their toxicity, development of biological resistance, length of treatment and high cost. Thus, it is important to continue the search for new effective and less toxic treatments. The anti-Leishmania activity of sixteen semisynthetic lupane triterpenoids derivatives of betulin (BT01 to BT09) and betulinic acid (AB10 to AB16) were evaluated. Drug interactions between the active compounds and one current antileishmanial drug, miltefosine, were assessed using the fixed ratio isobologram method. In addition, effects on the cell cycle, apoptosis/necrosis events, morphology and DNA integrity were studied. The derivatives BT06 (3β-Hydroxy-(20R)-lupan-29-oxo-28-yl-1H-？imidazole-1-carboxylate)and AB13 (28-(1H-imidazole-1-yl)-3,28-dioxo-lup-1？,20(29)-dien-2-yl-1H-imidazole-1-carboxy？late)were found to be the most active, with IC50 values of 50.8 μM and 25.8 μM, respectively. Interactions between these two compounds and miltefosine were classified as synergistic, with the most effective association being between AB13 and miltefosine, where decreases of IC50 values to 6 μM were observed, similar to the miltefosine activity alone. AB13 induced significant morphological changes, while both derivatives produced anti-proliferative activity through cell cycle arrest at the G0/G1 phase. Neither of these derivatives induced significant apoptosis/necrosis, as indicated by phosphatidylserine externalization and DNA fragmentation assays. In addition, neither of the derivatives induced death in macrophage cell lines. Thus, they do not present any potential risk of toxicity for the host cells. This study has identified the betulin derivative BT06 and the betulinic acid derivative AB13 as promising molecules in the development of new alternative therapies for leishmaniasis, including those involving combined-therapy with miltefosine.
References
[1]
WHO (2010) Control of the leishmaniases. World Health Organization technical reportseries (949) xii–186, xii-xiii, 1-186.
[2]
Croft SL, Barrett MP, Urbina JA (2005) Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 21 (11) 508–512. doi: 10.1016/j.pt.2005.08.026
[3]
Croft SL, Sundar S, Fairlamb AH (2006) Drug Resistance in Leishmaniasis. Clin Microbiol Rev 19 (1) 111–126. doi: 10.1128/cmr.19.1.111-126.2006
[4]
Kappagoda S, Singh U, Blackburn BG (2011) Antiparasitic therapy. Mayo Clin Proc 86 (6) 561–583. doi: 10.4065/mcp.2011.0203
[5]
Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, et al. (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2 (8) 494–501. doi: 10.1016/s1473-3099(02)00347-x
[6]
Gazanion E, Vergnes B, Seveno M, Garcia D, Oury B, et al. (2011) In vitro activity of nicotinamide/antileishmanial drug combinations. Parasitol Int 60 (1) 19–24. doi: 10.1016/j.parint.2010.09.005
[7]
Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, et al. (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, noninferiority, randomised controlled trial. Lancet 377 (9764) 477–486. doi: 10.1016/s0140-6736(10)62050-8
[8]
Fuertes MA, Nguewa PA, Castilla J, Alonso C, Pérez JM (2008) Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr Med Chem 15: 433–439. doi: 10.2174/092986708783503221
[9]
Lee N, Bertholet S, Debrabant A, Muller J, Duncan R, et al. (2002) Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ 9 (1) 53–64. doi: 10.1038/sj.cdd.4400952
[10]
van Zandbergen G, Lüder CGK, Heussler V, Duszenko M (2010) Programmed cell death in unicellular parasites: a prerequisite for sustained infection? Trends in Parasitology 26 (10) 477–483. doi: 10.1016/j.pt.2010.06.008
[11]
Moreira W, Leprohon P, Ouellette M (2011) Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania. Cell Death Dis 1;2: e201 doi: 10.1038/cddis.2011.83.
[12]
Sereno D, Holzmuller P, Mangot I, Cuny G, Ouaissi A, et al. (2001) Antimonial-mediated DNA fragmentation in Leishmania infantum amastigotes. Antimicrob Agents Chemother 45 (7) 2064–2069. doi: 10.1128/aac.45.7.2064-2069.2001
[13]
Carvalho L, Luque-Ortega JR, López-Martín C, Castanys S, Rivas L, et al. (2011) The 8-aminoquinoline analogue sitamaquine causes oxidative stress in Leishmania donovani promastigotes by targeting succinate dehydrogenase. Antimicrob Agents Chemother 55 (9) 4204–4210. doi: 10.1128/aac.00520-11
[14]
Sen N, Das BB, Ganguly A, Mukherjee T, Tripathi G, et al. (2004) Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ 11: 924–936. doi: 10.1038/sj.cdd.4401435
[15]
Prada CF, Alvarez-Velilla R, Bala？a-Fouce R, Prieto C, Calvo-álvarez E, et al. (2013) Gimatecan and other camptothecin derivatives poison Leishmania DNA-topoisomerase IB leading to a strong leishmanicidal effect. Biochem Pharmacol 85 (10) 1433–40. doi: 10.1016/j.bcp.2013.02.024
[16]
Croft SL, Coombs GH (2003) Leishmaniasis– current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol 19 (11) 502–508. doi: 10.1016/j.pt.2003.09.008
[17]
Paris C, Loiseau PM, Bories C, Bréard J (2004) Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 48 (3) 852–959. doi: 10.1128/aac.48.3.852-859.2004
[18]
Baglin I, Mitaine-Offer AC, Nour M, Tan K, Cavé C, et al. (2003) A review of natural and modified betulinic, ursolic and echinocystic acid derivatives as potential antitumor and anti-HIV agents. Mini Rev Med Chem 3 (6) 525–539. doi: 10.2174/1389557033487917
Mukherjee R, Kumar V, Srivastava SK, Agarwal SK, Burman AC (2006) Betulinic acid derivatives as anticancer agents: structure activity relationship. Anticancer Agents Med Chem 6 (3) 271–9. doi: 10.2174/187152006776930846
[21]
Ryu SY, Oak MH, Yoon SK, Cho DI, Yoo GS, et al. (2000) Anti-allergic and anti-inflammatory triterpenes from the herb of Prunella vulgaris. Planta Med 66: 358–360. doi: 10.1055/s-2000-8531
[22]
RajuGautam S, Jachak M (2009) Recent Developments in Infammatory Natural Products. Med Res Rev 29 (5) 767–820. doi: 10.1002/med.20156
[23]
Cichewicz RH, Kouzi SA (2004) Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med Res Rev 24: 90–11. doi: 10.1002/med.10053
[24]
Xiong J, Kashiwada Y, Chen CH, Qian K, Morris-Natschke SL, et al. (2010) Conjugates of betulin derivatives with AZT as potent anti-HIV agents. Bioorg Med Chem 18 (17) 6451–69 doi: 10.1016/j.bmc.2010.06.092.
[25]
Yogeeswari P, Sriram D (2005) Betulinic acid and its derivatives: a review on their biological properties. Curr Med Chem 12 (6) 657–66. doi: 10.2174/0929867053202214
[26]
Filho AAS, Resende DO, Fukui MJ, Santos FF, Pauletti PM, et al. (2009) In vitro antileishmanial, antiplasmodial and cytotoxic activities of phenolics and triterpenoids from Baccharis dracunculifolia D. C. (Asteraceae). Fitoterapia 80 (8) 478–482. doi: 10.1016/j.fitote.2009.06.007
[27]
Alakurtti S, Heiska T, Kiriazis A, Sacerdoti-Sierra N, Jaffe CL, et al. (2010) Synthesis and anti-leishmanial activity of heterocyclic betulin derivatives. Bioorg Med Chem 18 (4) 1573–1582. doi: 10.1016/j.bmc.2010.01.003
Santos RC, Salvador JAR, Marín S, Cascante M (2009) Novel semisynthetic derivatives of betulin and betulinic acid with cytotoxic activity. Bioorg Med Chem 17 (17) 6241–6250. doi: 10.1016/j.bmc.2009.07.050
[30]
Santos RC, Salvador JAR, Cortés R, Pachón G, Marín S, et al. (2011) New betulinic acid derivatives induce potent and selective antiproliferative activity through cell cycle arrest at the S phase and caspase dependent apoptosis in human cancer cells. Biochimie 93 (6) 1065–1075. doi: 10.1016/j.biochi.2011.02.014
[31]
Santos RC, Salvador JAR, Marín S, Cascante M, Moreira JN, et al. (2010) Synthesis and structure-activity relationship study of novel cytotoxic carbamate and N-acylheterocyclic bearing derivatives of betulin and betulinic acid. Bioorg Med Chem 18 (12) 4385–4396. doi: 10.1016/j.bmc.2010.04.085
[32]
Denizot F, Lang R (1986) Rapid colorimetric assay for cell growth and survival.Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89 (2) 271–277. doi: 10.1016/0022-1759(86)90368-6
[33]
Wagenpfeil S, Treiber U, Lehmer A (2006) Statistical analysis of combined dose effects for experiments with two agents. Artif Intell Med 37 (1) 65–71. doi: 10.1016/j.artmed.2005.01.011
[34]
Darzynkiewicz Z, Juan G, Bedner E (2001) Determining cell cycle stages by flow cytometry. New York: Curr. Protoc. Cell Biol. Chapter 8 Unit 8.4. doi: 10.1002/0471143030.cb0804s01.
[35]
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger CA (1995) Novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184: 39–51. doi: 10.1016/0022-1759(95)00072-i
[36]
Sporn MB, Liby KT, Yore MM, Fu L, Lopchuk JM, et al. (2011) New Synthetic Triterpenoids: Potent Agents for Prevention and Treatment of Tissue Injury Caused by Inflammatory and Oxidative Stress. J Nat Prod 74 (3) 537–545. doi: 10.1021/np100826q
[37]
Dutta A, Ghoshal A, Mandal D, Mondal NB, Banerjee S, et al. (2007) Racemoside A, an anti-leishmanial, water-soluble, natural steroidal saponin, induces programmed cell death in Leishmania donovani. J Med Microbio 56: 1196–1204. doi: 10.1099/jmm.0.47114-0
[38]
Nakayama H, Desrivot J, Bories C, Franck X, Figadère B, et al. (2007) In vitro and in vivo antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Biomed Pharmacother 61: 186–8. doi: 10.1016/j.biopha.2007.02.001
[39]
Lakshmi V, Pandey K, Kapil A, Singh N, Samant M, et al. (2007) In vitro and in vivo leishmanicidal activity of Dysoxylum binectariferum and its fractions against Leishmania donovani. Phytomedicine 14: 36–42. doi: 10.1016/j.phymed.2005.10.002
[40]
Santin MR, Dos Santos AO, Nakamura CV, Dias Filho BP, Ferreira IC, et al. (2009) In vitro activity of the essential oil of Cymbopogon citratus and its major component (citral) on Leishmania amazonensis. Parasitol Res 105: 1489–96. doi: 10.1007/s00436-009-1578-7
[41]
Vermeersch M, da Luz RI, Toté K, Timmermans JP, Cos P, et al. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53 (9) 3855–9. doi: 10.1128/aac.00548-09
[42]
Chowdhury AR, Mandal S, Goswami A, Ghosh M, Mandal L, et al. (2003) Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy. Mol Med 9: 26–36.
[43]
Chowdhury S, Mukherjee T, Sengupta S, Chowdhury SR, Mukhopadhyay S, et al. (2011) Novel Betulin Derivatives as Antileishmanial Agents with Mode of Action Targeting Type IB DNA Topoisomerase. Mol Pharmacol 80: 694–703. doi: 10.1124/mol.111.072785
